nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—CYP3A4—type 2 diabetes mellitus	0.178	1	CbGaD
Tolterodine—CYP2C19—Gliclazide—type 2 diabetes mellitus	0.0297	0.0521	CbGbCtD
Tolterodine—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.029	0.051	CbGbCtD
Tolterodine—CYP2C9—Glipizide—type 2 diabetes mellitus	0.0265	0.0466	CbGbCtD
Tolterodine—CYP2C19—Chlorpropamide—type 2 diabetes mellitus	0.0252	0.0443	CbGbCtD
Tolterodine—CYP2C19—Pioglitazone—type 2 diabetes mellitus	0.0252	0.0443	CbGbCtD
Tolterodine—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.0247	0.0434	CbGbCtD
Tolterodine—CYP2C19—Rosiglitazone—type 2 diabetes mellitus	0.0233	0.0409	CbGbCtD
Tolterodine—CYP2C19—Tolbutamide—type 2 diabetes mellitus	0.0225	0.0395	CbGbCtD
Tolterodine—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.021	0.0369	CbGbCtD
Tolterodine—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.021	0.0369	CbGbCtD
Tolterodine—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.0194	0.034	CbGbCtD
Tolterodine—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0192	0.0337	CbGbCtD
Tolterodine—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0189	0.0333	CbGbCtD
Tolterodine—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.0187	0.0329	CbGbCtD
Tolterodine—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.0177	0.0311	CbGbCtD
Tolterodine—CYP2C9—Valsartan—type 2 diabetes mellitus	0.0171	0.03	CbGbCtD
Tolterodine—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0169	0.0296	CbGbCtD
Tolterodine—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.0159	0.0279	CbGbCtD
Tolterodine—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0154	0.0271	CbGbCtD
Tolterodine—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.0152	0.0268	CbGbCtD
Tolterodine—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.0145	0.0255	CbGbCtD
Tolterodine—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.0139	0.0245	CbGbCtD
Tolterodine—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0135	0.0237	CbGbCtD
Tolterodine—CYP2C19—Glyburide—type 2 diabetes mellitus	0.0129	0.0227	CbGbCtD
Tolterodine—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0122	0.0214	CbGbCtD
Tolterodine—CYP2C19—Losartan—type 2 diabetes mellitus	0.0118	0.0208	CbGbCtD
Tolterodine—CYP2C9—Glyburide—type 2 diabetes mellitus	0.0107	0.0189	CbGbCtD
Tolterodine—CYP2C9—Losartan—type 2 diabetes mellitus	0.00982	0.0173	CbGbCtD
Tolterodine—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00924	0.0162	CbGbCtD
Tolterodine—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00886	0.0156	CbGbCtD
Tolterodine—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00886	0.0156	CbGbCtD
Tolterodine—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00838	0.0147	CbGbCtD
Tolterodine—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00624	0.011	CbGbCtD
Tolterodine—CYP3A4—Losartan—type 2 diabetes mellitus	0.00571	0.01	CbGbCtD
Tolterodine—Labetalol—ADRB3—type 2 diabetes mellitus	0.000941	0.331	CrCbGaD
Tolterodine—Fesoterodine—CYP3A4—type 2 diabetes mellitus	0.000394	0.139	CrCbGaD
Tolterodine—Infection—Bromocriptine—type 2 diabetes mellitus	0.000356	0.00221	CcSEcCtD
Tolterodine—Flatulence—Gliclazide—type 2 diabetes mellitus	0.000355	0.0022	CcSEcCtD
Tolterodine—Urinary tract infection—Irbesartan—type 2 diabetes mellitus	0.000354	0.0022	CcSEcCtD
Tolterodine—Somnolence—Glimepiride—type 2 diabetes mellitus	0.000353	0.00219	CcSEcCtD
Tolterodine—Somnolence—Sitagliptin—type 2 diabetes mellitus	0.000352	0.00218	CcSEcCtD
Tolterodine—Diarrhoea—Repaglinide—type 2 diabetes mellitus	0.000352	0.00218	CcSEcCtD
Tolterodine—Fatigue—Pioglitazone—type 2 diabetes mellitus	0.000352	0.00218	CcSEcCtD
Tolterodine—Feeling abnormal—Glipizide—type 2 diabetes mellitus	0.000351	0.00218	CcSEcCtD
Tolterodine—Weight increased—Losartan—type 2 diabetes mellitus	0.00035	0.00217	CcSEcCtD
Tolterodine—Tachycardia—Bromocriptine—type 2 diabetes mellitus	0.00035	0.00217	CcSEcCtD
Tolterodine—Dyspepsia—Glimepiride—type 2 diabetes mellitus	0.00035	0.00217	CcSEcCtD
Tolterodine—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.000349	0.00217	CcSEcCtD
Tolterodine—Dyspepsia—Sitagliptin—type 2 diabetes mellitus	0.000349	0.00216	CcSEcCtD
Tolterodine—Gastrointestinal pain—Glipizide—type 2 diabetes mellitus	0.000348	0.00216	CcSEcCtD
Tolterodine—Fatigue—Glimepiride—type 2 diabetes mellitus	0.000342	0.00213	CcSEcCtD
Tolterodine—Arthralgia—Glyburide—type 2 diabetes mellitus	0.000342	0.00212	CcSEcCtD
Tolterodine—Fatigue—Sitagliptin—type 2 diabetes mellitus	0.000341	0.00212	CcSEcCtD
Tolterodine—Oedema peripheral—Metformin—type 2 diabetes mellitus	0.000341	0.00212	CcSEcCtD
Tolterodine—Pain—Sitagliptin—type 2 diabetes mellitus	0.000339	0.0021	CcSEcCtD
Tolterodine—Constipation—Sitagliptin—type 2 diabetes mellitus	0.000339	0.0021	CcSEcCtD
Tolterodine—Abdominal pain—Glipizide—type 2 diabetes mellitus	0.000337	0.00209	CcSEcCtD
Tolterodine—Feeling abnormal—Pioglitazone—type 2 diabetes mellitus	0.000336	0.00209	CcSEcCtD
Tolterodine—Urinary tract infection—Losartan—type 2 diabetes mellitus	0.000333	0.00207	CcSEcCtD
Tolterodine—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.000333	0.00207	CcSEcCtD
Tolterodine—Confusional state—Glyburide—type 2 diabetes mellitus	0.00033	0.00205	CcSEcCtD
Tolterodine—Angioedema—Gliclazide—type 2 diabetes mellitus	0.000329	0.00204	CcSEcCtD
Tolterodine—Oedema—Glyburide—type 2 diabetes mellitus	0.000328	0.00203	CcSEcCtD
Tolterodine—Feeling abnormal—Glimepiride—type 2 diabetes mellitus	0.000327	0.00203	CcSEcCtD
Tolterodine—Flatulence—Valsartan—type 2 diabetes mellitus	0.000326	0.00203	CcSEcCtD
Tolterodine—Feeling abnormal—Sitagliptin—type 2 diabetes mellitus	0.000326	0.00203	CcSEcCtD
Tolterodine—Gastrointestinal pain—Glimepiride—type 2 diabetes mellitus	0.000325	0.00202	CcSEcCtD
Tolterodine—Gastrointestinal pain—Sitagliptin—type 2 diabetes mellitus	0.000324	0.00201	CcSEcCtD
Tolterodine—Flatulence—Orlistat—type 2 diabetes mellitus	0.000322	0.002	CcSEcCtD
Tolterodine—Headache—Repaglinide—type 2 diabetes mellitus	0.000322	0.002	CcSEcCtD
Tolterodine—Oedema peripheral—Irbesartan—type 2 diabetes mellitus	0.000322	0.002	CcSEcCtD
Tolterodine—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000322	0.002	CcSEcCtD
Tolterodine—Sinusitis—Losartan—type 2 diabetes mellitus	0.000322	0.002	CcSEcCtD
Tolterodine—Flushing—Metformin—type 2 diabetes mellitus	0.000322	0.002	CcSEcCtD
Tolterodine—Somnolence—Bromocriptine—type 2 diabetes mellitus	0.000319	0.00198	CcSEcCtD
Tolterodine—Palpitations—Gliclazide—type 2 diabetes mellitus	0.000319	0.00198	CcSEcCtD
Tolterodine—Bronchitis—Ramipril—type 2 diabetes mellitus	0.000317	0.00197	CcSEcCtD
Tolterodine—Dyspepsia—Bromocriptine—type 2 diabetes mellitus	0.000315	0.00196	CcSEcCtD
Tolterodine—Visual impairment—Irbesartan—type 2 diabetes mellitus	0.000315	0.00196	CcSEcCtD
Tolterodine—Abdominal pain—Glimepiride—type 2 diabetes mellitus	0.000314	0.00195	CcSEcCtD
Tolterodine—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.000314	0.00195	CcSEcCtD
Tolterodine—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	0.000313	0.00194	CcSEcCtD
Tolterodine—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.000309	0.00192	CcSEcCtD
Tolterodine—Chest pain—Gliclazide—type 2 diabetes mellitus	0.000307	0.0019	CcSEcCtD
Tolterodine—Arthralgia—Gliclazide—type 2 diabetes mellitus	0.000307	0.0019	CcSEcCtD
Tolterodine—Constipation—Bromocriptine—type 2 diabetes mellitus	0.000306	0.0019	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Ramipril—type 2 diabetes mellitus	0.000306	0.0019	CcSEcCtD
Tolterodine—Anxiety—Gliclazide—type 2 diabetes mellitus	0.000306	0.0019	CcSEcCtD
Tolterodine—Asthenia—Glipizide—type 2 diabetes mellitus	0.000305	0.0019	CcSEcCtD
Tolterodine—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000305	0.00189	CcSEcCtD
Tolterodine—Flushing—Irbesartan—type 2 diabetes mellitus	0.000303	0.00188	CcSEcCtD
Tolterodine—Angioedema—Valsartan—type 2 diabetes mellitus	0.000303	0.00188	CcSEcCtD
Tolterodine—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.0003	0.00186	CcSEcCtD
Tolterodine—Dry mouth—Gliclazide—type 2 diabetes mellitus	0.0003	0.00186	CcSEcCtD
Tolterodine—Weight increased—Ramipril—type 2 diabetes mellitus	0.0003	0.00186	CcSEcCtD
Tolterodine—Angioedema—Orlistat—type 2 diabetes mellitus	0.000299	0.00186	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Glyburide—type 2 diabetes mellitus	0.000298	0.00185	CcSEcCtD
Tolterodine—Vertigo—Valsartan—type 2 diabetes mellitus	0.000298	0.00185	CcSEcCtD
Tolterodine—Flatulence—Metformin—type 2 diabetes mellitus	0.000297	0.00184	CcSEcCtD
Tolterodine—Confusional state—Gliclazide—type 2 diabetes mellitus	0.000297	0.00184	CcSEcCtD
Tolterodine—Feeling abnormal—Bromocriptine—type 2 diabetes mellitus	0.000295	0.00183	CcSEcCtD
Tolterodine—Vertigo—Orlistat—type 2 diabetes mellitus	0.000294	0.00182	CcSEcCtD
Tolterodine—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	0.000293	0.00182	CcSEcCtD
Tolterodine—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000293	0.00182	CcSEcCtD
Tolterodine—Palpitations—Valsartan—type 2 diabetes mellitus	0.000293	0.00182	CcSEcCtD
Tolterodine—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000293	0.00182	CcSEcCtD
Tolterodine—Infection—Gliclazide—type 2 diabetes mellitus	0.000292	0.00181	CcSEcCtD
Tolterodine—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000292	0.00181	CcSEcCtD
Tolterodine—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000291	0.00181	CcSEcCtD
Tolterodine—Palpitations—Orlistat—type 2 diabetes mellitus	0.000289	0.00179	CcSEcCtD
Tolterodine—Dyspepsia—Glyburide—type 2 diabetes mellitus	0.000288	0.00179	CcSEcCtD
Tolterodine—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000287	0.00178	CcSEcCtD
Tolterodine—Urinary tract infection—Ramipril—type 2 diabetes mellitus	0.000286	0.00177	CcSEcCtD
Tolterodine—Flushing—Losartan—type 2 diabetes mellitus	0.000286	0.00177	CcSEcCtD
Tolterodine—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000285	0.00177	CcSEcCtD
Tolterodine—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000284	0.00176	CcSEcCtD
Tolterodine—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.000283	0.00176	CcSEcCtD
Tolterodine—Chest pain—Valsartan—type 2 diabetes mellitus	0.000282	0.00175	CcSEcCtD
Tolterodine—Arthralgia—Valsartan—type 2 diabetes mellitus	0.000282	0.00175	CcSEcCtD
Tolterodine—Dizziness—Glipizide—type 2 diabetes mellitus	0.000281	0.00175	CcSEcCtD
Tolterodine—Anxiety—Valsartan—type 2 diabetes mellitus	0.000281	0.00174	CcSEcCtD
Tolterodine—Flatulence—Irbesartan—type 2 diabetes mellitus	0.00028	0.00174	CcSEcCtD
Tolterodine—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000279	0.00173	CcSEcCtD
Tolterodine—Chest pain—Orlistat—type 2 diabetes mellitus	0.000279	0.00173	CcSEcCtD
Tolterodine—Anxiety—Orlistat—type 2 diabetes mellitus	0.000278	0.00172	CcSEcCtD
Tolterodine—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000276	0.00171	CcSEcCtD
Tolterodine—Sinusitis—Ramipril—type 2 diabetes mellitus	0.000276	0.00171	CcSEcCtD
Tolterodine—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000272	0.00169	CcSEcCtD
Tolterodine—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000272	0.00169	CcSEcCtD
Tolterodine—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000271	0.00168	CcSEcCtD
Tolterodine—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.00027	0.00168	CcSEcCtD
Tolterodine—Oedema—Valsartan—type 2 diabetes mellitus	0.00027	0.00168	CcSEcCtD
Tolterodine—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.00027	0.00168	CcSEcCtD
Tolterodine—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.00027	0.00167	CcSEcCtD
Tolterodine—Infection—Valsartan—type 2 diabetes mellitus	0.000269	0.00167	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.000268	0.00166	CcSEcCtD
Tolterodine—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.000268	0.00166	CcSEcCtD
Tolterodine—Oedema—Orlistat—type 2 diabetes mellitus	0.000267	0.00166	CcSEcCtD
Tolterodine—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.000267	0.00166	CcSEcCtD
Tolterodine—Headache—Glipizide—type 2 diabetes mellitus	0.000267	0.00166	CcSEcCtD
Tolterodine—Palpitations—Metformin—type 2 diabetes mellitus	0.000267	0.00165	CcSEcCtD
Tolterodine—Infection—Orlistat—type 2 diabetes mellitus	0.000265	0.00165	CcSEcCtD
Tolterodine—Flatulence—Losartan—type 2 diabetes mellitus	0.000264	0.00164	CcSEcCtD
Tolterodine—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000263	0.00163	CcSEcCtD
Tolterodine—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000262	0.00163	CcSEcCtD
Tolterodine—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000262	0.00162	CcSEcCtD
Tolterodine—Angioedema—Irbesartan—type 2 diabetes mellitus	0.00026	0.00161	CcSEcCtD
Tolterodine—Oedema peripheral—Ramipril—type 2 diabetes mellitus	0.00026	0.00161	CcSEcCtD
Tolterodine—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000259	0.00161	CcSEcCtD
Tolterodine—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000259	0.00161	CcSEcCtD
Tolterodine—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000257	0.0016	CcSEcCtD
Tolterodine—Chest pain—Metformin—type 2 diabetes mellitus	0.000257	0.00159	CcSEcCtD
Tolterodine—Vertigo—Irbesartan—type 2 diabetes mellitus	0.000256	0.00159	CcSEcCtD
Tolterodine—Headache—Pioglitazone—type 2 diabetes mellitus	0.000255	0.00159	CcSEcCtD
Tolterodine—Visual impairment—Ramipril—type 2 diabetes mellitus	0.000254	0.00158	CcSEcCtD
Tolterodine—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000254	0.00157	CcSEcCtD
Tolterodine—Constipation—Gliclazide—type 2 diabetes mellitus	0.000252	0.00156	CcSEcCtD
Tolterodine—Pain—Gliclazide—type 2 diabetes mellitus	0.000252	0.00156	CcSEcCtD
Tolterodine—Headache—Glimepiride—type 2 diabetes mellitus	0.000249	0.00154	CcSEcCtD
Tolterodine—Headache—Sitagliptin—type 2 diabetes mellitus	0.000248	0.00154	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000246	0.00153	CcSEcCtD
Tolterodine—Oedema—Metformin—type 2 diabetes mellitus	0.000246	0.00153	CcSEcCtD
Tolterodine—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000245	0.00152	CcSEcCtD
Tolterodine—Flushing—Ramipril—type 2 diabetes mellitus	0.000245	0.00152	CcSEcCtD
Tolterodine—Angioedema—Losartan—type 2 diabetes mellitus	0.000245	0.00152	CcSEcCtD
Tolterodine—Infection—Metformin—type 2 diabetes mellitus	0.000245	0.00152	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000243	0.00151	CcSEcCtD
Tolterodine—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000242	0.0015	CcSEcCtD
Tolterodine—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000242	0.0015	CcSEcCtD
Tolterodine—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000242	0.0015	CcSEcCtD
Tolterodine—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000241	0.0015	CcSEcCtD
Tolterodine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000241	0.0015	CcSEcCtD
Tolterodine—Vertigo—Losartan—type 2 diabetes mellitus	0.000241	0.00149	CcSEcCtD
Tolterodine—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000241	0.00149	CcSEcCtD
Tolterodine—Somnolence—Valsartan—type 2 diabetes mellitus	0.00024	0.00149	CcSEcCtD
Tolterodine—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000238	0.00148	CcSEcCtD
Tolterodine—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000237	0.00147	CcSEcCtD
Tolterodine—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000237	0.00147	CcSEcCtD
Tolterodine—Palpitations—Losartan—type 2 diabetes mellitus	0.000237	0.00147	CcSEcCtD
Tolterodine—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000235	0.00146	CcSEcCtD
Tolterodine—Asthenia—Glyburide—type 2 diabetes mellitus	0.000235	0.00146	CcSEcCtD
Tolterodine—Fatigue—Valsartan—type 2 diabetes mellitus	0.000233	0.00145	CcSEcCtD
Tolterodine—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000233	0.00144	CcSEcCtD
Tolterodine—Oedema—Irbesartan—type 2 diabetes mellitus	0.000232	0.00144	CcSEcCtD
Tolterodine—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000232	0.00144	CcSEcCtD
Tolterodine—Constipation—Valsartan—type 2 diabetes mellitus	0.000231	0.00143	CcSEcCtD
Tolterodine—Infection—Irbesartan—type 2 diabetes mellitus	0.000231	0.00143	CcSEcCtD
Tolterodine—Fatigue—Orlistat—type 2 diabetes mellitus	0.00023	0.00143	CcSEcCtD
Tolterodine—Pain—Orlistat—type 2 diabetes mellitus	0.000228	0.00142	CcSEcCtD
Tolterodine—Arthralgia—Losartan—type 2 diabetes mellitus	0.000228	0.00142	CcSEcCtD
Tolterodine—Chest pain—Losartan—type 2 diabetes mellitus	0.000228	0.00142	CcSEcCtD
Tolterodine—Anxiety—Losartan—type 2 diabetes mellitus	0.000227	0.00141	CcSEcCtD
Tolterodine—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000227	0.00141	CcSEcCtD
Tolterodine—Headache—Bromocriptine—type 2 diabetes mellitus	0.000225	0.00139	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000224	0.00139	CcSEcCtD
Tolterodine—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000224	0.00139	CcSEcCtD
Tolterodine—Dry mouth—Losartan—type 2 diabetes mellitus	0.000223	0.00138	CcSEcCtD
Tolterodine—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000221	0.00137	CcSEcCtD
Tolterodine—Confusional state—Losartan—type 2 diabetes mellitus	0.00022	0.00137	CcSEcCtD
Tolterodine—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.00022	0.00137	CcSEcCtD
Tolterodine—Somnolence—Metformin—type 2 diabetes mellitus	0.000219	0.00136	CcSEcCtD
Tolterodine—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000219	0.00136	CcSEcCtD
Tolterodine—Oedema—Losartan—type 2 diabetes mellitus	0.000219	0.00136	CcSEcCtD
Tolterodine—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000218	0.00136	CcSEcCtD
Tolterodine—Infection—Losartan—type 2 diabetes mellitus	0.000217	0.00135	CcSEcCtD
Tolterodine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000217	0.00135	CcSEcCtD
Tolterodine—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000217	0.00134	CcSEcCtD
Tolterodine—Atomoxetine—HTR2C—type 2 diabetes mellitus	0.000216	0.0761	CrCbGaD
Tolterodine—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000214	0.00133	CcSEcCtD
Tolterodine—Tachycardia—Losartan—type 2 diabetes mellitus	0.000213	0.00132	CcSEcCtD
Tolterodine—Fatigue—Metformin—type 2 diabetes mellitus	0.000212	0.00132	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000212	0.00131	CcSEcCtD
Tolterodine—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000211	0.00131	CcSEcCtD
Tolterodine—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000211	0.00131	CcSEcCtD
Tolterodine—Constipation—Metformin—type 2 diabetes mellitus	0.00021	0.00131	CcSEcCtD
Tolterodine—Angioedema—Ramipril—type 2 diabetes mellitus	0.00021	0.0013	CcSEcCtD
Tolterodine—Brompheniramine—CYP2E1—type 2 diabetes mellitus	0.000208	0.0732	CrCbGaD
Tolterodine—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000206	0.00128	CcSEcCtD
Tolterodine—Vertigo—Ramipril—type 2 diabetes mellitus	0.000206	0.00128	CcSEcCtD
Tolterodine—Headache—Glyburide—type 2 diabetes mellitus	0.000205	0.00127	CcSEcCtD
Tolterodine—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000204	0.00127	CcSEcCtD
Tolterodine—Palpitations—Ramipril—type 2 diabetes mellitus	0.000203	0.00126	CcSEcCtD
Tolterodine—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000203	0.00126	CcSEcCtD
Tolterodine—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000201	0.00125	CcSEcCtD
Tolterodine—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000201	0.00125	CcSEcCtD
Tolterodine—Fatigue—Irbesartan—type 2 diabetes mellitus	0.0002	0.00124	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000199	0.00124	CcSEcCtD
Tolterodine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000199	0.00124	CcSEcCtD
Tolterodine—Pain—Irbesartan—type 2 diabetes mellitus	0.000199	0.00123	CcSEcCtD
Tolterodine—Constipation—Irbesartan—type 2 diabetes mellitus	0.000199	0.00123	CcSEcCtD
Tolterodine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000197	0.00122	CcSEcCtD
Tolterodine—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000196	0.00121	CcSEcCtD
Tolterodine—Chest pain—Ramipril—type 2 diabetes mellitus	0.000196	0.00121	CcSEcCtD
Tolterodine—Anxiety—Ramipril—type 2 diabetes mellitus	0.000195	0.00121	CcSEcCtD
Tolterodine—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000195	0.00121	CcSEcCtD
Tolterodine—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000195	0.00121	CcSEcCtD
Tolterodine—Somnolence—Losartan—type 2 diabetes mellitus	0.000194	0.00121	CcSEcCtD
Tolterodine—Asthenia—Valsartan—type 2 diabetes mellitus	0.000194	0.0012	CcSEcCtD
Tolterodine—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000192	0.00119	CcSEcCtD
Tolterodine—Asthenia—Orlistat—type 2 diabetes mellitus	0.000192	0.00119	CcSEcCtD
Tolterodine—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000191	0.00119	CcSEcCtD
Tolterodine—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000191	0.00119	CcSEcCtD
Tolterodine—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.00019	0.00118	CcSEcCtD
Tolterodine—Confusional state—Ramipril—type 2 diabetes mellitus	0.000189	0.00117	CcSEcCtD
Tolterodine—Fatigue—Losartan—type 2 diabetes mellitus	0.000188	0.00117	CcSEcCtD
Tolterodine—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000187	0.00116	CcSEcCtD
Tolterodine—Oedema—Ramipril—type 2 diabetes mellitus	0.000187	0.00116	CcSEcCtD
Tolterodine—Pain—Losartan—type 2 diabetes mellitus	0.000187	0.00116	CcSEcCtD
Tolterodine—Constipation—Losartan—type 2 diabetes mellitus	0.000187	0.00116	CcSEcCtD
Tolterodine—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000185	0.00115	CcSEcCtD
Tolterodine—Headache—Gliclazide—type 2 diabetes mellitus	0.000184	0.00114	CcSEcCtD
Tolterodine—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000184	0.00114	CcSEcCtD
Tolterodine—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000183	0.00114	CcSEcCtD
Tolterodine—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000183	0.00113	CcSEcCtD
Tolterodine—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.00018	0.00112	CcSEcCtD
Tolterodine—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000179	0.00111	CcSEcCtD
Tolterodine—Dizziness—Valsartan—type 2 diabetes mellitus	0.000179	0.00111	CcSEcCtD
Tolterodine—Dizziness—Orlistat—type 2 diabetes mellitus	0.000177	0.0011	CcSEcCtD
Tolterodine—Asthenia—Metformin—type 2 diabetes mellitus	0.000177	0.0011	CcSEcCtD
Tolterodine—Disopyramide—CYP3A4—type 2 diabetes mellitus	0.000176	0.062	CrCbGaD
Tolterodine—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000173	0.00107	CcSEcCtD
Tolterodine—Phenprocoumon—CYP3A4—type 2 diabetes mellitus	0.000173	0.0608	CrCbGaD
Tolterodine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000171	0.00106	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000171	0.00106	CcSEcCtD
Tolterodine—Headache—Valsartan—type 2 diabetes mellitus	0.000169	0.00105	CcSEcCtD
Tolterodine—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000168	0.00105	CcSEcCtD
Tolterodine—Headache—Orlistat—type 2 diabetes mellitus	0.000167	0.00104	CcSEcCtD
Tolterodine—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000167	0.00103	CcSEcCtD
Tolterodine—Somnolence—Ramipril—type 2 diabetes mellitus	0.000167	0.00103	CcSEcCtD
Tolterodine—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000165	0.00102	CcSEcCtD
Tolterodine—Dizziness—Metformin—type 2 diabetes mellitus	0.000163	0.00101	CcSEcCtD
Tolterodine—Fatigue—Ramipril—type 2 diabetes mellitus	0.000162	0.001	CcSEcCtD
Tolterodine—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000161	0.001	CcSEcCtD
Tolterodine—Constipation—Ramipril—type 2 diabetes mellitus	0.00016	0.000995	CcSEcCtD
Tolterodine—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000159	0.000986	CcSEcCtD
Tolterodine—Asthenia—Losartan—type 2 diabetes mellitus	0.000157	0.000973	CcSEcCtD
Tolterodine—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.000154	0.000959	CcSEcCtD
Tolterodine—Headache—Metformin—type 2 diabetes mellitus	0.000154	0.000957	CcSEcCtD
Tolterodine—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000154	0.000953	CcSEcCtD
Tolterodine—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.000153	0.000951	CcSEcCtD
Tolterodine—Phenprocoumon—ALB—type 2 diabetes mellitus	0.000151	0.0531	CrCbGaD
Tolterodine—Diarrhoea—Losartan—type 2 diabetes mellitus	0.00015	0.000928	CcSEcCtD
Tolterodine—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.000148	0.00092	CcSEcCtD
Tolterodine—Headache—Irbesartan—type 2 diabetes mellitus	0.000146	0.000903	CcSEcCtD
Tolterodine—Dizziness—Losartan—type 2 diabetes mellitus	0.000145	0.000897	CcSEcCtD
Tolterodine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.000138	0.000857	CcSEcCtD
Tolterodine—Headache—Losartan—type 2 diabetes mellitus	0.000137	0.00085	CcSEcCtD
Tolterodine—Asthenia—Ramipril—type 2 diabetes mellitus	0.000134	0.000835	CcSEcCtD
Tolterodine—Orphenadrine—CYP2E1—type 2 diabetes mellitus	0.000131	0.0461	CrCbGaD
Tolterodine—Brompheniramine—CYP3A4—type 2 diabetes mellitus	0.000131	0.0461	CrCbGaD
Tolterodine—Chlorphenamine—CYP3A4—type 2 diabetes mellitus	0.000128	0.0453	CrCbGaD
Tolterodine—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000128	0.000796	CcSEcCtD
Tolterodine—Dizziness—Ramipril—type 2 diabetes mellitus	0.000124	0.000769	CcSEcCtD
Tolterodine—Headache—Ramipril—type 2 diabetes mellitus	0.000117	0.000729	CcSEcCtD
Tolterodine—Atomoxetine—CYP3A4—type 2 diabetes mellitus	0.000108	0.038	CrCbGaD
Tolterodine—Orphenadrine—CYP3A4—type 2 diabetes mellitus	8.25e-05	0.029	CrCbGaD
Tolterodine—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	5.67e-06	6.33e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	5.67e-06	6.33e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GCG—type 2 diabetes mellitus	5.63e-06	6.28e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—SLC2A4—type 2 diabetes mellitus	5.63e-06	6.28e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—C3—type 2 diabetes mellitus	5.62e-06	6.27e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—C3—type 2 diabetes mellitus	5.61e-06	6.25e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.57e-06	6.21e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.57e-06	6.21e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—C3—type 2 diabetes mellitus	5.55e-06	6.19e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—RELA—type 2 diabetes mellitus	5.48e-06	6.11e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PPARG—type 2 diabetes mellitus	5.44e-06	6.07e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	5.36e-06	5.98e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	5.35e-06	5.97e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	5.35e-06	5.97e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—HIF1A—type 2 diabetes mellitus	5.35e-06	5.96e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—AGT—type 2 diabetes mellitus	5.34e-06	5.96e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IRS2—type 2 diabetes mellitus	5.33e-06	5.95e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—INS—type 2 diabetes mellitus	5.33e-06	5.95e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—AGT—type 2 diabetes mellitus	5.33e-06	5.94e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.32e-06	5.93e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GNB3—type 2 diabetes mellitus	5.32e-06	5.93e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	5.29e-06	5.91e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—HMOX1—type 2 diabetes mellitus	5.29e-06	5.9e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IRS2—type 2 diabetes mellitus	5.28e-06	5.89e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—AGT—type 2 diabetes mellitus	5.28e-06	5.88e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CALM1—type 2 diabetes mellitus	5.25e-06	5.86e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—RELA—type 2 diabetes mellitus	5.24e-06	5.85e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CALM1—type 2 diabetes mellitus	5.24e-06	5.84e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—LEP—type 2 diabetes mellitus	5.24e-06	5.84e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—APOE—type 2 diabetes mellitus	5.24e-06	5.84e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CAT—type 2 diabetes mellitus	5.22e-06	5.83e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—LEP—type 2 diabetes mellitus	5.22e-06	5.82e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—APOE—type 2 diabetes mellitus	5.22e-06	5.82e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CALM1—type 2 diabetes mellitus	5.19e-06	5.79e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	5.18e-06	5.77e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—LEP—type 2 diabetes mellitus	5.17e-06	5.77e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—APOE—type 2 diabetes mellitus	5.17e-06	5.77e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—APOA1—type 2 diabetes mellitus	5.16e-06	5.76e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—APOA1—type 2 diabetes mellitus	5.11e-06	5.7e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—APOB—type 2 diabetes mellitus	5.07e-06	5.66e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	5e-06	5.57e-05	CbGpPWpGaD
Tolterodine—CHRM4—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.99e-06	5.56e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.94e-06	5.51e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.94e-06	5.51e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GSTM1—type 2 diabetes mellitus	4.93e-06	5.5e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.92e-06	5.49e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.91e-06	5.47e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	4.9e-06	5.46e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	4.9e-06	5.46e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	4.89e-06	5.46e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.89e-06	5.46e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—ALB—type 2 diabetes mellitus	4.89e-06	5.45e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.87e-06	5.44e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	4.87e-06	5.43e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.85e-06	5.41e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	4.85e-06	5.41e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—LPL—type 2 diabetes mellitus	4.84e-06	5.4e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	4.83e-06	5.38e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	4.8e-06	5.36e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	4.8e-06	5.36e-05	CbGpPWpGaD
Tolterodine—CHRM5—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.77e-06	5.33e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	4.77e-06	5.32e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	4.77e-06	5.32e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	4.77e-06	5.32e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	4.76e-06	5.31e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	4.74e-06	5.29e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ADCY5—type 2 diabetes mellitus	4.74e-06	5.29e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.73e-06	5.28e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—GPX1—type 2 diabetes mellitus	4.72e-06	5.27e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.7e-06	5.24e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3R1—type 2 diabetes mellitus	4.68e-06	5.22e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—NOS3—type 2 diabetes mellitus	4.68e-06	5.22e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.67e-06	5.21e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.67e-06	5.21e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	4.66e-06	5.2e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	4.66e-06	5.19e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.66e-06	5.19e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	4.62e-06	5.16e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.62e-06	5.15e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.61e-06	5.14e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	4.6e-06	5.13e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CD36—type 2 diabetes mellitus	4.6e-06	5.13e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PPP2CA—type 2 diabetes mellitus	4.54e-06	5.07e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	4.54e-06	5.06e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.53e-06	5.05e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	4.5e-06	5.02e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—INS—type 2 diabetes mellitus	4.47e-06	4.99e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.47e-06	4.99e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—INS—type 2 diabetes mellitus	4.46e-06	4.97e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	4.45e-06	4.97e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.42e-06	4.93e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—INS—type 2 diabetes mellitus	4.42e-06	4.93e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	4.41e-06	4.92e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.4e-06	4.91e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.39e-06	4.89e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	4.36e-06	4.86e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—MTHFR—type 2 diabetes mellitus	4.36e-06	4.86e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.34e-06	4.85e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	4.34e-06	4.85e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.34e-06	4.84e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.33e-06	4.83e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.32e-06	4.82e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	4.32e-06	4.82e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.31e-06	4.81e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.31e-06	4.81e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	4.31e-06	4.8e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.31e-06	4.8e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—SRC—type 2 diabetes mellitus	4.3e-06	4.8e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.29e-06	4.79e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	4.28e-06	4.77e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	4.28e-06	4.77e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	4.28e-06	4.77e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTGS2—type 2 diabetes mellitus	4.28e-06	4.77e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PPARA—type 2 diabetes mellitus	4.28e-06	4.77e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.27e-06	4.76e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.27e-06	4.76e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.25e-06	4.74e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	4.23e-06	4.72e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	4.2e-06	4.69e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	4.19e-06	4.68e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.19e-06	4.68e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	4.18e-06	4.66e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	4.16e-06	4.64e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	4.14e-06	4.62e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—AGT—type 2 diabetes mellitus	4.14e-06	4.62e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—SRC—type 2 diabetes mellitus	4.12e-06	4.6e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.11e-06	4.58e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.1e-06	4.57e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	4.07e-06	4.54e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CALM1—type 2 diabetes mellitus	4.07e-06	4.54e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—APOE—type 2 diabetes mellitus	4.06e-06	4.53e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.06e-06	4.52e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.01e-06	4.48e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—APOA1—type 2 diabetes mellitus	4.01e-06	4.47e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	4.01e-06	4.47e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	3.97e-06	4.43e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	3.93e-06	4.39e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.92e-06	4.38e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.92e-06	4.38e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	3.91e-06	4.37e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.91e-06	4.36e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.91e-06	4.36e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	3.9e-06	4.35e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.87e-06	4.32e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.87e-06	4.32e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	3.87e-06	4.32e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	3.87e-06	4.32e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.85e-06	4.29e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	3.81e-06	4.25e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	3.78e-06	4.21e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.77e-06	4.21e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	3.75e-06	4.18e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	3.73e-06	4.16e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	3.71e-06	4.14e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	3.71e-06	4.14e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	3.71e-06	4.14e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	3.7e-06	4.13e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	3.69e-06	4.12e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	3.69e-06	4.12e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.68e-06	4.11e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—RELA—type 2 diabetes mellitus	3.68e-06	4.11e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	3.66e-06	4.08e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—RELA—type 2 diabetes mellitus	3.64e-06	4.07e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.61e-06	4.03e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PPARG—type 2 diabetes mellitus	3.53e-06	3.94e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—INS—type 2 diabetes mellitus	3.47e-06	3.87e-05	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.36e-06	3.75e-05	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.35e-06	3.74e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.33e-06	3.72e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.32e-06	3.7e-05	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.32e-06	3.7e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.31e-06	3.69e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.3e-06	3.68e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.29e-06	3.67e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.27e-06	3.64e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	3.25e-06	3.63e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	3.22e-06	3.6e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.2e-06	3.57e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	3.2e-06	3.57e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	3.19e-06	3.56e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	3.18e-06	3.55e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ALB—type 2 diabetes mellitus	3.18e-06	3.55e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	3.16e-06	3.53e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.15e-06	3.51e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	3.14e-06	3.5e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.14e-06	3.5e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.11e-06	3.47e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.11e-06	3.47e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.1e-06	3.46e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.07e-06	3.43e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.05e-06	3.41e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	3.05e-06	3.4e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.04e-06	3.39e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—NOS3—type 2 diabetes mellitus	3.04e-06	3.39e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3R1—type 2 diabetes mellitus	3.04e-06	3.39e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.01e-06	3.36e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	2.97e-06	3.31e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	2.92e-06	3.26e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	2.91e-06	3.25e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.9e-06	3.24e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—IL6—type 2 diabetes mellitus	2.9e-06	3.23e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	2.9e-06	3.23e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SRC—type 2 diabetes mellitus	2.89e-06	3.23e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SRC—type 2 diabetes mellitus	2.86e-06	3.2e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	2.85e-06	3.18e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	2.84e-06	3.17e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.83e-06	3.15e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.82e-06	3.14e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	2.8e-06	3.12e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	2.8e-06	3.12e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.79e-06	3.11e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTGS2—type 2 diabetes mellitus	2.78e-06	3.1e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IL6—type 2 diabetes mellitus	2.78e-06	3.1e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	2.77e-06	3.09e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	2.77e-06	3.09e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	2.77e-06	3.09e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	2.73e-06	3.05e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.67e-06	2.98e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	2.62e-06	2.92e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.59e-06	2.89e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.59e-06	2.88e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	2.57e-06	2.87e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.56e-06	2.86e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.56e-06	2.86e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	2.56e-06	2.85e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.54e-06	2.84e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	2.54e-06	2.83e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.54e-06	2.83e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.51e-06	2.8e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	2.49e-06	2.78e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	2.45e-06	2.73e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	2.44e-06	2.72e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	2.41e-06	2.69e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—AKT1—type 2 diabetes mellitus	2.15e-06	2.4e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	2.13e-06	2.37e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	2.08e-06	2.33e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.95e-06	2.18e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL6—type 2 diabetes mellitus	1.95e-06	2.17e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL6—type 2 diabetes mellitus	1.93e-06	2.15e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	1.91e-06	2.13e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	1.83e-06	2.04e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	1.83e-06	2.04e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.8e-06	2.01e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.8e-06	2.01e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.78e-06	1.99e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	1.67e-06	1.87e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—AKT1—type 2 diabetes mellitus	1.4e-06	1.56e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	1.29e-06	1.43e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	1.27e-06	1.42e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	8.4e-07	9.37e-06	CbGpPWpGaD
